Lilly Among Stocks With At Least $10 M In Insider Sales Recently

 While the total value of insider sales for these stocks may be higher, we focused on sales worth $10 million or more. Out of the stocks that met this criterion, we selected the 10 stocks with insider sales ranging from $10 million to $20 million, prioritizing those with the highest insider sales within this range for further analysis.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points.

For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $10 million year-to-date, and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $10 million in insider sales since the beginning of the year.

An array of pharmaceutical pills with the company's logo on the bottle.

Eli Lilly and Company (NYSE:LLY)

Highest Individual Sale: $19,507,205.25

Number of Sales Above $10 million: 24

Market Capitalization: $835.05 billion

In the middle of this list of 10 stocks with $10 million in insider sales recently is a multinational pharmaceutical firm, Eli Lilly and Company (NYSE:LLY). Commonly known as Lilly, the Indianapolis, Indiana-headquartered company has offices in 18 countries and its products have reached approximately 125 countries worldwide. It is also one of the top 10 stocks to buy according to Lone Pine Capital.

Lilly is known for its clinical depression drugs Prozac (1986), Cymbalta (2004), and its antipsychotic medication Zyprexa (1996). Its primary revenue drivers are the diabetes drugs Humalog (1996) and Trulicity (2014).

Since the beginning of the year, one insider made 24 sales of Eli Lilly and Company (NYSE:LLY) shares. One of the transactions was worth $19.51 million, during which the insider sold 21,025 shares at a price of $927.81 per share. Currently, the stock is trading at $929.72, having gained 20.43% year-to-date.

Recently, Lilly announced it plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the U.S. This brings the company's total capital expansion commitments to more than $50 billion since 2020.

Last week, the company also confirmed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a reversible Bruton's tyrosine kinase (BTK) inhibitor. The treatment is recommended for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have previously been treated with a BTK inhibitor. The news caused its shares to jump 2.713%, from $905.16 to $929.72 per share.

Twenty analysts have an average “Moderate Buy” rating on Eli Lilly and Company (NYSE:LLY) stock, with a price target of $1,007.50 per share, according to MarketBeat.

Overall LLY ranks 5th on our list of the stocks with at least $10 million in insider sales recently.

https://finance.yahoo.com/news/eli-lilly-company-lly-among-021842033.html